Extended-Duration Thromboprophylaxis Among Acute Medically Ill Patients: An Unmet Need

被引:8
|
作者
Korjian, Serge [1 ]
Daaboul, Yazan [1 ]
Halaby, Rim [1 ]
Goldhaber, Samuel Z. [2 ]
Cohen, Alexander T. [3 ]
Singh, Kiran [1 ]
Susheela, Ammu T. [1 ]
Harrington, Robert A. [4 ]
Hull, Russell D. [5 ]
Hernandez, Adrian F. [6 ,7 ]
Gibson, C. Michael [1 ]
机构
[1] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Med,Cardiovasc Div, 330 Brookline Ave,RW-459, Boston, MA 02215 USA
[2] Harvard Univ, Sch Med, Dept Med, Brigham & Womens Hosp,Cardiovasc Div, Boston, MA 02115 USA
[3] Guys & St Thomas NHS Trust, Dept Haematol, London, England
[4] Stanford Univ, Sch Med, Dept Med, Stanford, CA 94305 USA
[5] Univ Calgary, Fac Med, Dept Med, Foothills Hosp, Calgary, AB, Canada
[6] Duke Univ, Sch Med, Duke Clin Res Inst, Durham, NC USA
[7] Duke Univ, Sch Med, Dept Med, Durham, NC 27706 USA
关键词
thromboprophylaxis; acute medically ill; venous thromboembolism; deep vein thrombosis; pulmonary embolism; anticoagulation; VENOUS THROMBOEMBOLISM PROPHYLAXIS; TISSUE FACTOR EXPRESSION; CHRONIC KIDNEY-DISEASE; COST-EFFECTIVENESS; ANTITHROMBOTIC PROPHYLAXIS; ENDOTHELIAL-CELLS; HEART-FAILURE; RISK-FACTORS; INFLAMMATION; PREVENTION;
D O I
10.1177/1074248415601894
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Acute medical illnesses are associated with a prolonged elevation in inflammatory markers that predisposes patients to thrombosis beyond the duration of their hospital stay. In parallel, both observational and randomized data have demonstrated a rate of post discharge venous thromboembolic events that often exceeds that observed in the hospital setting. Despite this significant residual risk of venous thromboembolic events following discharge among acute medically ill patients, no therapeutic strategies have been recommended to address this unmet need. Available randomized trials have demonstrated the efficacy of extending the duration of thromboprophylaxis with available anticoagulants; however, the efficacy is offset, at least in part, by an increase in bleeding events. Identification of the optimal therapeutic strategies, treatment duration, and risk assessment tools that reconcile both efficacy and safety of extended-duration thromboprophylaxis among acute medically ill patients is an area of ongoing investigation.
引用
收藏
页码:227 / 232
页数:6
相关论文
共 50 条
  • [1] A clinical focus on the use of extended-duration thromboprophylaxis in medically ill patients
    Snoga, Jenna L.
    Benitez, Rebekah M.
    Kim, Subin
    Creager, Olivia
    Lusk, Kathleen A.
    [J]. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2021, 78 (12) : 1057 - 1065
  • [3] Reducing the burden of venous thromboembolism in the acute medically ill population with extended-duration thromboprophylaxis
    Ageno, Walter
    Hunt, Beverley J.
    [J]. EUROPEAN HEART JOURNAL SUPPLEMENTS, 2018, 20 (0E) : E6 - E11
  • [4] Direct oral anticoagulants for extended-duration thromboprophylaxis in hospitalized medically ill patients: are we there yet?
    Majed S. Al Yami
    Osamah M. Alfayez
    Sawsan M. Kurdi
    Razan Alsheikh
    [J]. Journal of Thrombosis and Thrombolysis, 2017, 44 : 1 - 8
  • [5] Direct oral anticoagulants for extended-duration thromboprophylaxis in hospitalized medically ill patients: are we there yet?
    Al Yami, Majed S.
    Alfayez, Osamah M.
    Kurdi, Sawsan M.
    Alsheikh, Razan
    [J]. JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2017, 44 (01) : 1 - 8
  • [6] Effect of extended duration of thromboprophylaxis for medically ill patients
    Wang, Xing
    Chen, Yuqi
    Wen, Dingke
    You, Chao
    Ma, Lu
    [J]. EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2023, 113 : 22 - 30
  • [7] Symptomatic event reduction with extended-duration betrixaban in acute medically ill hospitalized patients
    Gibson, C. Michael
    Nafee, Tarek
    Yee, Megan K.
    Chi, Gerald
    Korjian, Serge
    Daaboul, Yazan
    AlKhalfan, Fahad
    Kerneis, Mathieu
    Goldhaber, Samuel Z.
    Hull, Russel
    Hernandez, Adrian F.
    Cohen, Alexander T.
    Harrington, Robert A.
    [J]. AMERICAN HEART JOURNAL, 2018, 198 : 84 - 90
  • [8] Extended-duration rivaroxaban thromboprophylaxis in acutely ill medical patients: MAGELLAN study protocol
    Cohen, Alexander Thomas
    Spiro, Theodore Erich
    Buller, Harry Roger
    Haskell, Lloyd
    Hu, Dayi
    Hull, Russell
    Mebazaa, Alexandre
    Merli, Geno
    Schellong, Sebastian
    Spyropoulos, Alex
    Tapson, Victor
    [J]. JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2011, 31 (04) : 407 - 416
  • [9] Extended-duration rivaroxaban thromboprophylaxis in acutely ill medical patients: MAGELLAN study protocol
    Alexander Thomas Cohen
    Theodore Erich Spiro
    Harry Roger Büller
    Lloyd Haskell
    Dayi Hu
    Russell Hull
    Alexandre Mebazaa
    Geno Merli
    Sebastian Schellong
    Alex Spyropoulos
    Victor Tapson
    [J]. Journal of Thrombosis and Thrombolysis, 2011, 31 : 407 - 416
  • [10] Extended thromboprophylaxis with betrixaban: a new standard for acute medically ill patients
    Cohen, Alexander T.
    [J]. EUROPEAN HEART JOURNAL SUPPLEMENTS, 2018, 20 (0E) : E1 - E2